Immunohistochemical expressions of fatty acid synthase and phosphorylated c-Met in thyroid carcinomas of follicular origin

International Journal of Clinical and Experimental Pathology

Volumn 4, Issue 8, 2011, Pages 755-764

  Liu, Jing ^a   Brown, Robert E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

C met; Fatty acid synthase; Immunohistochemistry; Thyroid carcinoma

Indexed keywords

FATTY ACID SYNTHASE; SCATTER FACTOR RECEPTOR; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; BIOSYNTHESIS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; THYROID TUMOR;

ADENOCARCINOMA, FOLLICULAR; FATTY ACID SYNTHETASE COMPLEX; HUMANS; IMMUNOHISTOCHEMISTRY; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863076579     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Smith S, Witkowski A, Joshi AK. Structural and functional organization of the animal fatty acid synthase. Prog Lipid Res 2003; 42: 289-317.
2. Wakil SJ. Fatty acid synthase, a proficient multi-functional enzyme. Biochemistry 1989; 28: 4523-4530.
3. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 7: 763-777.
4. Zhang L, Joshi AK, Smith S. Cloning, expression, characterization, and interaction of two components of a human mitochondrial fatty acid synthase. J Biol Chem 2003; 278: 40067-40074.
5. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006; 66: 5977-5980.
6. Liu H, Liu JY, Wu X, Zhang JT. Biochemistry, molecular biology, and pharmacology of fatty acid synthase, and emerging therapeutic target and diagnosis/prognosis marker. Int J Biochem Mol Biol 2010; 1: 69-89.
7. Liu H, Liu Y, Zhang JT. A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. Mol Cancer Ther 2008; 7: 263-270.
8. Yang Y, Liu H, Li Z, Zhao Z, Yip Schneider M, Fan Q, Schmidt CM, Chiorean EG, Xie J, Cheng L, Chen JH, Zhang JT. Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers. Int J Biochem Mol Biol 2011; 2: 89-98.
9. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006; 66: 5977-5980.
10. Sekiguchi M, Shiroko Y, Arai T, Kishino T, Sugawara I, Kusakabe T, Suzuki T, Yamashita T, Obara T, Ito K, Hasumi K. Biological characteristics and chemosensitivity profile of four human anaplastic thyroid carcinoma cell lines. Biomed Pharmacother 2001; 55: 466-474.
11. Uddin S, Siraj AK, Al Rasheed M, Ahmed M, Bu R, Myers, JN, Al Nuaim A, Al Sobhi S, Al Dayel F, Bavi P, Hussain AR, Al Kuraya KS. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J Clin Endocrinol Metab 2008; 93: 4088-4097.
12. Coleman DT, Bigelow R, Cardelli JA. Inhibition of fatty acid synthase by luteolin posttranscriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation. Mol Cancer Ther 2009; 8: 214-224.
13. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, Lupu R. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 2004; 101: 10715-10720.
14. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the met proto-oncogene product. Science 1991; 251: 802-904.
15. Galland F, Stefanova M, Lafage M, Birnbaum D. Localization of the 5' end of the MCF2 oncogene to human chromosome 15q15-q23. Cytogenet Cell Genet 1992; 60: 114-116.
16. Cooper CS. The met oncogene: from detection by transfection to transmembrane receptor for hepatocyte growth factor. Oncogene 1992; 7: 3-7.
17. Chatopadhyay C, El Naggar AK, Williams MD, Clayman GL. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma. Head Neck 2008; 30: 991-1000.
18. Looyenga BD, Furge KA, Dykema KJ, Koeman J, Swiatek PJ Giordano TJ, West AB, Resau JH, The BT, Mackeigan JP. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Pro Natl Acad Sci USA 2011; 108: 1439-1444.
19. Scarpino S, Duranti E, Stoppacciaro A, Pilozzi E, Natoli G, Sciacchitano S, Luciani E, Ruco L. COX-2 is induced by HGF stimulation in Metpositive thyroid papillary carcinoma cells and is involved in tumour invasiveness. J Pathol 2009; 218: 487-494.
20. Todaro M, Iovino F, Eterno V, Cammareri P, Gambara G, Espina V, Gulotta G, Dieli F, Giordano S, De Maria R, Stassi G. Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res 2010; 70: 8874-8885.
21. Lin CI, Whang EE, Donner DB, Du J, Lorch J, He F, Jiang X, Price BD, Moore FD Jr, Ruan DT. Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol Cancer Res 2010; 8: 1217-1226.
22. Ruco LP, Ranalli T, Marzullo A, Bianco P, Prat M, Comoglio PM, Baroni CD. Expression of Met protein in thyroid tumours. J Pathol 1996; 180: 266-270.
23. Bartolone L, Vermiglio F, Finocchiaro MD, Violi MA, French D, Pontecorvi A, Trimarchi F, Benvenga S. Thyroid follicular oncogenesis in iodine-deficient and iodine-sufficient areas:search for alterations of the ras, met and bFGF oncogenes and of the Rb anti-oncogene. J Endocrinol Invest 1998; 21: 680-687.
24. Lupu R, Menendez JA. Pharmacological inhibitors of fatty acid synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr Pharm Biotechnol 2006; 7: 483-493.
25. Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 2010; 17: 351-360.
26. Pizer ES, Wood FD, Heine HS, Romantsey FE, Pasternack GR, Kuhaida FP. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 1996; 56: 1189-1193.
27. Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot L, Townsend CA, Kuhajda FP. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 2000; 60: 213-218.
28. Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS, Nelson JB. Increased fatty acid synthase as a therapeutic target in androgenindependent prostate cancer progression. Prostate 2001; 47: 102-110.
29. Alli PM, Pinn ML, Jaffee EM, McFadden JM, Kuhajda FP. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 2005; 24: 39-46.
30. Orita H, Coulter J, Tully E, Kuhajda FP, Gabrielson E. Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors. Clin Cancer Res 2008; 14: 2458-2464.
31. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 2004; 64: 2070-2075.
32. Ruggeri RM, Vitarelli E, Barresi G, Trimarchi F, Benvenga S, Trovato M. The tyrosine kinase receptor c-met, its cognate ligand HGF and the tyrosine kinase receptor trasducers STATs, PI3K and RHO in thyroid nodules associated with Hashimoto's thyroiditis: an immunohistochemical characterization. Eur J Histochem 2010 Jun 3; 54: e24.
33. Uddin S, Jehan Z, Ahmed M, Alyan A, Al Dayel F, Hussain A, Bavi P, Al Kuraya KS. Over expression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and its inhibition potentiates cisplatin induced apoptosis. Mol Med 2011; 17: 635-645.
34. Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J, Brozzetti S, Staniscia T, Chen X, Dombrowski F, Evert M. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 2011; 140: 1071-1083.
35. Van de Sande T, Roskams T, Lerut E, Joniau S, Van Poppel H, Verhoeven G, Swinnen JV. Highlevel expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J Pathol 2005; 206: 214-219.
36. Uddin S, Hussain AR, Ahmed M, Abubaker J, Al Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al Dayel F, Bavi P, Al Kuraya KS. High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target. Am J Gastroenterol 2009; 104: 1790-1801.
37. Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, Lupu R. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. Int J Oncol 2004; 24: 1369-1383.
38. Liu J, Brown RE. Morphoproteomics demonstrates activation of mammalian target of rapamycin (MTOR) pathway in papillary thyroid carcinomas with nuclear translocation of MTOR in aggressive histologic variants. Mod Pathol 2011 Aug 5. Doi: 10. 1038/ modpathol. 2011. 121 [Epub ahead of print].
39. Uddin S, Hussain AR, Ahmed M, Bu R, Ahmed SO, Ajarim D, Al Dayel F, Bavi P, Al Kuraya KS. Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma. Mol Cancer Ther 2010; 9: 1244-1255.
40. Hung CM, Kuo DH, Chou CH, Su YC, Ho CT, Way TD. Osthole suppresses hepatocyte growth factor (HGF)-induced epithelialmesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells. J Agric Food Chem 2011; 59: 9683-9690.
41. Yoshizawa Y, Yamada Y, Kanayama S, Shigetomi H, Kawaguchi R, Yoshida S, Nagai A, Furukawa N, Oi H, Kobayashi H. Signaling pathway involved in cyslooxygenase-2 upregulation by hepatocyte growth factor in endometrial cancer cells. Oncol Rep 2011; 26: 957-964.
42. Carr BI, Wang Z, Wang M, Cavallini A, D'Alessandro R, Refolo MG. c-Met-Akt pathwaymediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. Cancer Biol Ther 2011 Sep 15; 12. [Epub ahead of print].
43. Pavone LM, Cattaneo F, Rea S, De Pasquale V, Spina A, Sauchelli E, Mastellone V, Ammendola R. Intracellular signaling cascades triggered by the NK1 fragment of hepatocyte growth factor in human prostate epithelial cell line PNT1A. Cell Signal 2011 Jul 12. [Epub ahead of print].
44. Fresno Vara JA, Cassado E, de Castro J, Cejas P, Belda Iniesta C, Gonzalez Baron M. PI3K/ Akt signaling pathway and cancer. Cancer Treat Rev 2004; 30: 193-204.
45. Schaeper U, Behring NH, Fuchs KP, Sachs M, Kempkes B, Birchmeier W. Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J Cell Biol 2000; 149: 1419-1432.
46. Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000; 16: 202-208.
47. Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK, Koay ES. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neupositive breast cancer. Mol Cell Proteomics 2005; 4: 1686-1696.
48. Liu J, Brown RE. Morphoproteomics demonstrates activation of the mTOR pathway in anaplastic thyroid carcinoma: a preliminary observation. Ann Clin Lab Sci 2010; 40: 211-217.
49. Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995; 118: 1131-1136.
50. Haq M, Harmer C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin Endocrinol (Oxf) 2005; 63: 87-93.
51. Mills SC, Haq M, Smellie WJ, Harmer C. Hürthle cell carcinoma of the thyroid: retrospective review of 62 patients treated at Royal Marsden Hospital between 1946 and 2003. Eur J Surg Oncol 2009; 35: 230-234.
52. Barnabei A, Ferretti E, Baldelli R, Procaccini A, Spriano G, Appetecchia M. Hürthle cell tumours of the thyroid. Personal experience and review of the literature. Act Otorhinolaryngol Ital 2009; 29: 305-311.
53. Feldman PS, Horvath E, Kovacs K. Ultrastructure of three Hürthle cell tumors of the thyroid. Cancer 1972; 30: 1279-1285.